Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL0911 for chemotherapy-induced thrombocytopenia
CTR20202250Phase 3Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Nov 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of QL0911 in chemotherapy-induced thrombocytopenia (CIT), sponsored by Qilu Pharmaceutical. Started Nov 2020; status: completed.
02
Drugs
QL0911
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on CTR20202250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202250.